TrumpRx delayed as senators question if it’s a giant scam with Big Pharma
Summary
Ars Technica reports that TrumpRx, a planned direct-to-consumer platform for discounted prescription drugs, is delayed as lawmakers question its legality and oversight. Senators request details on how the Office of Inspector General will supervise the platform and enforce anti-kickback provisions, citing concerns about conflicts of interest and potential steering to high-cost medications via telehealth partners. The article also references prior investigations into DTC pharma platforms and possible connections to BlinkRx and Donald Trump Jr., highlighting regulatory scrutiny over pricing and access implications.